While the percentage of NSCLC patients with somatic PTPN11 mutations in their tumours is relatively low, it is roughly equivalent to the frequency of ALK translocations, the targeting of which has revolutionized the treatment of NSCLC. This evidence concerns the gene PTPN11 and neoplasm.